This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Is a Surprise Coming for Radius Health (RDUS) This Earnings Season?
by Zacks Equity Research
Radius Health (RDUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Moving Average Crossover Alert: Radius Health
by Zacks Equity Research
Radius Health, Inc. (RDUS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Radius Health Is in Oversold Territory: What???s Next?
by Tirthankar Chakraborty
Radius Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Amgen's Osteoporosis Drug Evenity Gets Approval in Europe
by Zacks Equity Research
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Why Is Radius Health (RDUS) Down 6.9% Since Last Earnings Report?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius Health (RDUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 18.75% and 2.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Radius Health Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Radius Health.
Radius Health (RDUS) Up 20.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Radius (RDUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid
by Zacks Equity Research
Radius (RDUS) reports a narrower-then-expected loss and beats sales estimates in the second quarter of 2019.
Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 9.41% and 0.64%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View
by Zacks Equity Research
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
Radius Health (RDUS) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues
by Zacks Equity Research
Radius Health (RDUS) posts narrower-than-expected Q1 loss but Tymlos sales disappoint.
Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 1.05% and -14.22%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Small Drug Stocks Outlook: Near-Term Prospects Encouraging
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.
Will Radius Health (RDUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
by Zacks Equity Research
Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.
Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
by Zacks Equity Research
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.
Why Is Radius Health (RDUS) Up 5.2% Since Last Earnings Report?
by Zacks Equity Research
Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales
by Zacks Equity Research
Radius Health (RDUS) posts narrower-than-expected Q4 loss as Tymlos sales gain traction and capture additional market share.
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.